BridgeBio Pharma BBIO Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's financing cash flow?
- BridgeBio Pharma (BBIO) reported financing cash flow of $549.89M in Q1 2026.
- How has BridgeBio Pharma's financing cash flow changed year-over-year?
- BridgeBio Pharma's financing cash flow increased by 811.5% year-over-year, from $60.33M to $549.89M.
- What does financing cash flow mean?
- The net cash flow resulting from debt and equity financing activities.
- How do you interpret financing cash flow?
- Positive values indicate net capital raising, while negative values indicate debt repayment or capital returns to shareholders.
- How does financing cash flow compare across companies?
- Highly dependent on the company's current stage in the business lifecycle.